Biora Therapeutics, Inc. (4ZU0)
XSTU 
Summary
4ZU0 Chart
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Testing in advanced animal model planned in Q4 f or smaller, 00-size BioJet device with largest capacity of any ingestible injectable
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2024. Company management will host a webcast and conference call on Thursday, November 14, 2024, after the close of financial markets.
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
Biora Therapeutics, Inc. (BIOR) Q2 2024 Earnings Call Transcript
Biora Therapeutics, Inc. Dividends
Biora Therapeutics, Inc. Earnings
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | 0.18 EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | - EPS |
| 24 Mar 2025 Date | | - Cons. EPS | - EPS |
| 11 Nov 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | 0.18 EPS |
| 15 May 2024 Date | | - Cons. EPS | - EPS |
Biora Therapeutics, Inc. (4ZU0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Biora Therapeutics, Inc. ever had a stock split?
Biora Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Aditya P. Mohanty M.B.A. CEO | XSTU Exchange | US74319F1075 ISIN |
| United States Country | 58 Employees | - Last Dividend | 18 Oct 2024 Last Split | 19 Jun 2020 IPO Date |
Overview
Biora Therapeutics, Inc. is a pioneering force in the biotechnology sector, focusing on the clinical-stage development of innovative oral biotherapeutics. With its operations rooted in the United States, Biora Therapeutics is on a mission to revolutionize the delivery and efficacy of treatments for various diseases. Initially known as Progenity, Inc., the company underwent a strategic rebranding in April 2022, adopting the name Biora Therapeutics, Inc. This change mirrored its sharpened focus on advancing its portfolio of therapeutic solutions. Since its inception in 2010, with headquarters in San Diego, California, Biora Therapeutics has been at the forefront of using advanced technology to create more efficient and patient-friendly treatments for chronic and acute conditions.
Products and Services
- NaviCap
- BioJet
This innovative product stands as Biora Therapeutics' answer to the challenges of treating gastrointestinal tract diseases more effectively. NaviCap is a targeted oral delivery platform specifically designed for the direct delivery of therapeutics within the gastrointestinal tract. Its primary goal is to significantly enhance the treatment outcomes for patients suffering from inflammatory bowel diseases. By focusing on precise delivery, NaviCap aims to improve the efficacy and minimize the side effects of treatments, offering a promising alternative to traditional therapeutic approaches.
BioJet marks a transformative step towards the needle-free administration of large molecules crucial for managing chronic diseases. This systemic oral delivery platform is engineered to replace traditional injections with an oral delivery method that eliminates the need for needles. The novelty of BioJet lies in its capability to facilitate the absorption of large molecules directly into the bloodstream through the gastrointestinal tract, thereby broadening the scope of oral biotherapeutics. This innovation holds the potential to greatly improve patient compliance and convenience in the chronic disease management landscape.
Contact Information
